{
  "name": "Selank",
  "category": "peptide",
  "evidenceGrade": "C",
  "riskProfile": "low",
  "description": "A synthetic analogue of the immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics (Russia). Approved as an anxiolytic in Russia. Enhances BDNF expression and has nootropic and immune-modulating properties.",
  "mechanisms": [
    "BDNF upregulation",
    "GABA modulation",
    "Immune system modulation (IL-6, T-helper balance)",
    "Enkephalin stabilization"
  ],
  "dosage": {
    "standard": "250-500mcg intranasal, 1-3x/day",
    "range": "150-750mcg/day",
    "notes": "Intranasal administration. Approved in Russia. Typical course is 2-4 weeks."
  },
  "keyFindings": [
    "Approved anxiolytic in Russia with clinical trial data",
    "Increased BDNF mRNA expression in hippocampus (animal studies)",
    "Anxiolytic without sedation or cognitive impairment"
  ],
  "interactions": [
    "Theoretical interaction with benzodiazepines or other GABAergic drugs"
  ],
  "sideEffects": [
    "Nasal irritation",
    "Mild fatigue (rare)"
  ],
  "contraindications": [
    "Pregnancy",
    "Autoimmune conditions (theoretical)"
  ],
  "tags": [
    "peptide",
    "nootropic",
    "anxiolytic",
    "immune",
    "russian-research"
  ],
  "estimatedMonthlyCost": {
    "low": 25,
    "mid": 50,
    "high": 100,
    "currency": "USD"
  },
  "id": "prod-selank",
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T14:50:14.774Z",
  "createdAt": "2026-02-04T14:50:14.774Z"
}